Supporting Information

Nose-to-brain drug delivery by HS15 micelles for Brain Targeting of insoluble ${\bf drug}$

Wei Zhang^a, Long Wan^b, Meiqi Han^c, Wen Guo^a, Zhiqi Wang^a, Xinyue Zhang^a, Xuyang Liu^a, Jiahao Wang^a, Yuling Mao^{a*}

^a Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103
Wenhua Road, Shenyang, Liaoning Province 110016, China

^b Department of Pharmacy, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang 110001, Liaoning, China

^c Department of Microbiology and Biochemical Pharmacy, School of Medical Devices, Shenyang Pharmaceutical University, Shenyang 110016, China

The corresponding author $\!\!\!\!\!^*$

Yuling Mao

E-mail address: maoyuling@syphu.edu.cn

 Table S1 The particle sizes of HS15-AGO respectively with CSF and PBS solution.

	In Cerebrospinal Fluid (CSF) (nm)			In Phosphate buffered saline (PBS) (nm)		
1.0	13.31	12.92	13.02	14.17	13.90	13.69
2.0	13.34	13.94	14.00	14.05	13.76	14.89
6.0	14.05	13.76	14.89	14.82	14.04	14.60
10.0	16.21	15.43	14.78	14.17	17.85	14.17
14.0	17.85	14.83	15.29	15.81	14.99	15.40
24.0	19.13	19.36	16.17	16.63	16.06	15.35

Table S2 The vitro release data of HS15-AGO in NF and CSF.

	In Nasal Fluid (NF) (%)			In Cerebrospinal Fluid (CSF) (%)		
0.5 h	41.0	43.4	39.5	38.9	36.8	39.4
1.0 h	61.0	60.8	58.4	51.0	50.2	52.4
2.0 h	71.8	72.6	70.6	72.9	73.3	75.1
4.0 h	93.7	95.0	93.7	91.7	91.6	93.2
6.0 h	96.2	100.3	97.3	96.3	96.1	97.6
8.0 h	99.1	98.3	95.8	102.5	102.3	104.0
10.0 h	101.9	101.2	99.5	100.9	100.0	102.7

Table S3 The vitro release data of AGO in NF and CSF.

	In Nasal Fluid (NF) (%)			In Cerebrospinal Fluid (CSF)(%)		
0.5 h	53.1	54.1	49.9	45.7	44.5	44.8
1.0 h	67.7	66.9	68.5	70.2	71.4	68.2
2.0 h	97.9	96.1	99.6	94.6	96.2	92.1
4.0 h	102.3	101.4	102.4	102.9	98.3	96.5
6.0 h	103.0	101.7	105.3	105.6	104.6	102.2
8.0 h	104.6	100.6	106.0	109.5	108.7	107.5
10.0 h	107.2	102.9	108.8	110.4	109.7	108.8